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Human immunodeficiency virus type 2 (HIV-2) infection, unlike HIV-1 infection, is normally characterized
by low rates of CD4 depletion and low-to-undetectable viremia. We found that the frequency of Gag-specific
CD4 T cells featured positive correlations with the expression of markers of CD4 activation and a negative
correlation with peripheral blood mononuclear cell-associated proviral load in infection with HIV-2, in contrast
with HIV-1. Moreover, HIV-2-infected individuals exhibited a greater ability to respond to HIV-1 Gag peptides
(heterologous responses). Our data suggest a potential link between HIV-2-specific CD4 responses, immune
activation, and viral control, which may in turn relate to the better prognosis associated with HIV-2 infection.
Infection with human immunodeficiency virus type 2 (HIV-2)
is associated with slow disease progression and, in the majority
of infected adults, a limited impact on mortality (12, 18, 24).
CD4 depletion occurs at a much lower rate with HIV-2 than
with HIV-1 disease (5, 12). Despite plasma viremia remaining
low to undetectable throughout HIV-2 infection (1, 14, 23),
levels of proviral DNA have been shown to be similar in both
HIV-1 and -2 infections (23, 25). A possible explanation for the
phenotypic differences between these two diseases is that they
reflect better control of viral replication by virus-specific im-
mune responses in HIV-2-infected individuals.
Although no major differences in the frequencies of HIV-
specific CD8 T cells have been reported in HIV-1- and HIV-
2-infected individuals (2, 4, 8, 9, 13, 15), HIV-2-specific CD8
T cells have been shown to recognize a broader range of viral
proteins (30) and to have a higher functional flexibility (16).
HIV-2-specific CD4 T cells have been less well characterized
(6, 7, 21, 22, 30), though a better preserved proliferative ca-
pacity has been shown (6).
Here, we show for the first time that HIV-2 Gag-specific
CD4 T-cell frequency correlated positively with CD4 activa-
tion and negatively with proviral load, raising the possibility of
a closer relationship between the state of immune hyperacti-
vation and virus-specific CD4 responses in HIV-2 infection.
We investigated homologous and heterologous Gag-spe-
cific CD4 T-cell responses in 19 HIV-2-infected and 19
HIV-1-infected individuals living in Portugal, matched for
CD4 depletion. All individuals were antiretroviral therapy
naı¨ve and without evidence of ongoing opportunistic infec-
tions or tumors. Their epidemiological and clinical features
are detailed in Table 1. The research was approved by the
Ethical Committee of the Faculdade de Medicina da Uni-
versidade de Lisboa.
Responses were assessed in terms of frequency and magni-
tude at the level of cytokine production. The relative contri-
bution of each cytokine-producing HIV-specific CD4 subset to
each individual’s response was also determined. The following
peptide sets were used: 20-mers, overlapping by 10 residues
and spanning residues 1 to 386 of HIV-2 ROD Gag (prepared
by MRC, United Kingdom), and 15-mers, overlapping by 11
residues and spanning the equivalent region of HIV-1 HXB2
Gag (AIDS Reagent Program, National Institutes of Health).
Peptide sets were combined in two separate pools, such that
the concentration of each peptide within a pool was 400 g/ml
and used at a final concentration of 2 g/ml/peptide. A total of
1  106 thawed peripheral blood mononuclear cells (PBMC)
were resuspended in 1 ml of complete medium (29) with 1
g/ml anti-CD28 (BD Biosciences, San Jose, CA) and cultured
for 6 h alone or together with the HIV-1 or HIV-2 Gag peptide
pools with the addition of 10 g/ml of brefeldin A (Sigma-
Aldrich, St. Louis, MO) after 1 hour of culture. Intracellular
cytokine staining for interleukin-2 (IL-2) and gamma inter-
feron (IFN-) was performed after surface staining for CD4
within 24 h of cell fixation as previously described (29). Results
were expressed as percentages of cytokine-positive CD4 T
cells within total CD4 T cells after background subtraction (anti-
CD28 stimulation alone). Phorbol myristate acetate (Sigma-Al-
drich)-plus-ionomycin (Calbiochem, Merck Biosciences, Not-
tingham, United Kingdom) stimulation was used as a positive
control (29). Each peptide pool was tested against thawed
PBMC from nine seronegative controls to establish an average
background response for each cytokine, alone or in combina-
tion, and cutoffs were set accordingly (range, 0 to 0.06%).
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Responses less than or equal to the corresponding assay cutoff
were assigned a value of 0.
The numbers of individuals mounting homologous re-
sponses were the same in both cohorts (15/19 [79%]). The total
magnitudes of these responses were similar for both groups,
which was reflected in the comparable frequencies of each of
the cytokine-producing subsets (Fig. 1A). Similar numbers of
homologous responders in both groups had multifunctional
Gag-specific CD4 responses, though 6/15 HIV-2-infected ho-
mologous responders had CD4 T cells that were positive only
for IL-2 (IL-2 single positivity) as their only detectable HIV-
specific response, compared to only 1/15 within the HIV-1
cohort (Fig. 1B and D).
Overall, we observed similar frequencies for CD4 T cells
able to recognize homologous Gag peptides in HIV-1 and
HIV-2 cohorts matched for CD4 depletion. In agreement with
previous reports (2, 6), the cytokine profiles of HIV-2 respond-
ers were dominated by IL-2 production alone or in combina-
tion with other cytokine-producing subsets, whereas in the
HIV-1 cohort, more responders had single IFN--producing
specific CD4 T cells forming part or all of their response.
In contrast, on assessment of heterologous responses, we
found that more patients with HIV-2 responded to HIV-1
peptides than did those with HIV-1 to HIV-2 peptides, though
this did not reach a level of significance (9/11 [82%] and 5/10
[50%], respectively; P  0.1224 [2 test]). The magnitude of
this response was significantly higher in the HIV-2 cohort than
in the HIV-1 cohort (P  0.0483) (Fig. 1A). The heterologous
response of the HIV-1 cohort was also significantly reduced
compared to its homologous response (P  0.0122), which was
largely due to the reduced frequency of IL-2 single-positive
CD4 (P  0.0105) (Fig. 1A). Of note, none of the HIV-1-
infected heterologous responders had detectable IFN-
IL-2 CD4 (Fig. 1A and E). Within the HIV-2 cohort, the
functionality of heterologous responses was similar to that
observed for homologous responses (Fig. 1B and C). However,
HIV-1 heterologous cytokine profiles were almost exclusively
dominated by IFN- single-positive CD4 (5/5, versus 4/9 in the
HIV-2 cohort) (Fig. 1E). The ability of a given individual,
independent of the type of HIV infection, to mount a heter-
ologous response was not dependent upon a detectable homol-
ogous response and vice versa.
In summary, we detected a clear difference in the magni-
tudes of CD4 T-cell response to heterologous peptides in
HIV-2-infected and HIV-1-infected individuals. Additionally,
in contrast to HIV-2, the frequency and magnitude of heter-
ologous responses in the HIV-1 cohort were significantly re-
duced compared to those of the homologous responses. It is
unlikely that the latter is related to the differing lengths of the
HIV-1 (15-mer) and HIV-2 (20-mer) peptides, as both types of
peptides have been shown to be equally efficient at revealing
HIV-specific CD4 responses (17). Moreover, the functionality
of heterologous responses was similar to that observed for
homologous responses in both cohorts. Our data revealing
responses to heterologous peptides in both HIV cohorts con-
tradict an earlier report (30). However, this probably reflects
differences in the populations assessed, CD8-depleted PBMC
versus CD4 T cells in our study, and the readouts, IFN-
enzyme-linked immunospot assays versus intracellular cyto-
kine staining used here. Moreover, other studies have shown
that PBMC isolated from HIV-2-infected individuals respond
to simian immunodeficiency virus recombinant proteins and
peptide pools, both in terms of proliferation (21, 22) and cy-
tokine production (2). Overall, these data suggest that HIV-2-
specific CD4 responses may feature a degree of flexibility sim-
ilar to that reported for their CD8 counterparts (16).
Next, we assessed the relationships between HIV-specific
responses and virological parameters. Plasma viremia was as-
sessed by reverse transcription-PCR (detection limit for
HIV-2, 200 RNA copies/ml, as described previously [27]; de-
tection limit for HIV-1, 50 RNA copies/ml; Roche Molecular
Systems, Branchburg, NJ), and PBMC-associated proviral load
was assessed by quantitative real-time PCR, as we have previ-
ously described (25).
Unlike others (11, 19, 20), we found no correlation between
the magnitude of HIV-specific CD4 responses and HIV-1 vire-
mia (Table 2), which probably relates to the absence of non-
progressors in our untreated cohort. The aviremic status of the
majority (18/19) of HIV-2-infected individuals precluded this
analysis. However, in contrast to the HIV-1 cohort, a signifi-
cant negative correlation between magnitude of homologous
IFN--producing CD4 responses and level of proviral DNA
was observed (Table 2). Of note, this differs from the current
paradigm that polyfunctionality of response, preservation of
IL-2 production in particular, is better related to viral control
(6). Interestingly, HIV-2-specific cytotoxic T-lymphocyte activ-
TABLE 1. Characterization of HIV-2- and HIV-1-infected cohorts
Characteristic
Value for cohort infected witha:
HIV-2 HIV-1
Total no. of subjects (males/females) 19 (11/8) 19 (5/14)
Age (yr) 47  3.2 (26–62) 41 2.3 (21–68)
Caucasians/others 8/11 12/7
CD4 T cell count (cells/l) 686  79 (188–1,436) 667 113 (133–2,174)
% CD4 T cells 30  3 (14–46) 27 3 (5–52)
Viremia (RNA copies/ml) 200 (200–4,006)b 8.6  104  4.1  104 (50 104–55  104)
Proviral DNA (copies/106 PBMC) 367  107 (20–1,296) 473 173 (61–2,016)
% HLA-DR within CD4 3.02  0.95 (0.16–2.66) 3.17 0.62 (0.26–9.8)
% HLA-DR CD38 within CD4 2.01  0.66 (0.07–8.45) 2.23 0.45 (0.13–2.75)
a Results are expressed as mean  standard error of the mean (range), except for the total number of subjects and for ethnicity. Two group comparisons were made
using unpaired t tests or the Mann-Whitney test, as appropriate. No statistical differences were found except for viremia, P  0.0005, after applying the appropriate
assay cutoff value to individuals with an undetectable viral load.
b Results are for 18/19 subjects.
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ity has also been shown to inversely relate to proviral DNA in
a Gambian cohort (3), further supporting the idea that the
immune response in general may be more effective in control-
ling virus replication/dissemination in HIV-2 infection. Al-
though the levels of proviral DNA are similar in HIV-2 and
HIV-1 infections, the dynamics of cell-associated proviral load
in relation to latency, productive infection, and cell death are
likely to be distinct given the disparity in viremia. This may
explain the contrasting associations between specific responses
and proviral DNA in these two infections.
Finally, we determined whether correlations between mark-
ers of CD4 T-cell activation and magnitude of HIV-specific
CD4 responses existed for either cohort. The factors driving
immune hyperactivation and whether their relative contribu-
tions to HIV immunopathogenesis are beneficial or deleteri-
ous are still subjects of ongoing debate (10, 26). This is further
FIG. 1. Homologous and heterologous responses to Gag peptides. HIV-specific CD4 responses were assessed by cytokine production at the
single-cell level after short-term culture with overlapping Gag peptides, and results are shown as the proportion of total CD4 T cells. Responses
of HIV-2 individuals against HIV-2 Gag peptides (homologous) and of those against HIV-1 Gag peptides (heterologous) are shown, as well as the
corresponding responses of an HIV-1 cohort. The total percentage of HIV-specific CD4 T cells able to recognize homologous or heterologous
peptide sets in each cohort (horizontally hatched bars) is illustrated in panel A. The frequencies of IL-2 single-positive (open bars) and IFN-
single-positive (gray bars) CD4 T cells and of CD4 T cells that were positive for both IL-2 and IFN- (black bars) are also illustrated. The bars
indicate the means  the standard errors of the means. Intercohort differences were assessed using unpaired t or Mann-Whitney U tests, as
appropriate, using GraphPad Prism version 4.00 (GraphPad Software Inc., SD). *, P 0.05. The heterogeneity of the HIV-specific CD4 responses
in terms of cytokine production is further defined for each responsive individual with respect to homologous and heterologous responses for the
HIV-2 cohort (panels B and C, respectively) and for the HIV-1 cohort (panels D and E, respectively). HIV-2 responders are identified by
uppercase letters A to S and HIV-1 responders by lowercase letters a to s. Each bar represents the total response for a given individual, with the
relative contributions of cytokine-producing HIV-specific CD4 subsets indicated as above.
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illustrated by the distinct rates of disease progression that
distinguish HIV-2- and HIV-1-infected patients despite exhib-
iting the same levels of immune activation at a given degree of
CD4 depletion (28). Freshly isolated PBMC were surface
stained and analyzed as previously described (28). Despite a
lack of significant correlations between absolute numbers or
frequency of circulating CD4 T cells and magnitude of the
specific CD4 T-cell response in either cohort, the HIV-2-
infected individuals exhibited significant positive correlations
between IL-2-producing homologous Gag responses and CD4
T-cell activation (Table 2). Although the possibility of a dele-
terious role for HIV-2-specific responses in driving immune
activation could be considered, their direct correlation with
CD4 T-cell activation uniquely observed in our HIV-2 cohort
suggests a possible counterbalance of the deleterious effects of
immune activation through an expansion of the virus-specific
responses. Moreover, this subset is characterized by IL-2-pro-
ducing cells and, therefore, likely to be enriched in central-mem-
ory cells with preserved proliferative capacity (20), capable of
generating more-differentiated, IFN--producing progeny, and
better able to target virally infected cells.
In conclusion, despite the similar frequencies and magni-
tudes of their homologous responses, HIV-2-infected individ-
uals had stronger heterologous responses than their HIV-1
counterparts. More importantly, we demonstrated that HIV-2
homologous responses alone correlated positively with CD4
activation and negatively with proviral load. Although the cor-
relative nature of this study precludes causal connections, it is
reasonable to speculate that the closer link between immune
activation and HIV-specific responses is related to the better
control of viral replication that characterizes HIV-2 disease
progression.
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